Top Healthcare stocks:
Healthcare shares were flat to lower in pre-market trade on
In healthcare stocks news, Lexicon Pharmaceuticals (
) shares were up 19.5% at $1.90 in pre-market trade on Monday after
the pharmaceutical company reported positive, top-line results in a
Phase 2 clinical trial of LX4211 in type 1 diabetes, which achieved
the primary endpoint of reducing mealtime insulin use as well as
several secondary endpoints, including improved glycemic
LXRX trades in a 52-week range of $1.54 to $3.18.
And, Retrophin (
) raised its revenue guidance for 2014 and 2015 as reimbursement
for its Chenodal drug to treat gallstones was "robust."
The pharmaceutical company said it now expects sales of between
$19 million and $21 million in 2014, up from the previous guidance
of $10 million to $12 million. For 2015, it expects sales between
$35 million and $40 million compared to the previous guidance range
between $19 million and $21 million.
Also, Cellular-therapy company NeoStem (
) said it agreed to acquire California Stem Cell, an Irvine,
Calif.-based stem-cell biotechnology company, in an all-stock deal
valued at about $34.1 million that will expand NeoStem's
development pipeline to include therapies for cancer.
NeoStem will pay for California Stem Cell by issuing an
aggregate of up to approximately 5.33 million shares of NeoStem
common stock, restricted and subject to a holding period, in
exchange for all of the CSC outstanding stock and options. As of
Friday's close, 5.33 million shares of NBS had a value of $34.1
Finally, Intercept Pharmaceuticals, Inc. (
) has announced efficacy and safety results from the Phase 3 POISE
trial of obeticholic acid for the treatment of primary biliary
cirrhosis. The findings will be presented at the International
Liver Congress of the European Association for the Study of the
Results showed notable improvements on key endpoints as early as
two weeks after treatment initiation. The proportion of patients
meeting the POISE primary endpoint was 10% in the placebo group,
47% in the 10 mg OCA group and 46% in the 5-10 mg OCA group.